Approval · Notice of Compliance 35199 · 2025
JEMPERLI: Notice of Compliance 35199
Issued April 16, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35199
- Date
- April 16, 2025
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: Jemperli is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or first recurrent endometrial cancer who are candidates for systemic therapy
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| JEMPERLI | Not yet assigned | — |
Medicinal ingredients
- DOSTARLIMAB 50 MG per ML